Risk of Fracture and the Concomitant Use of Bisphosphonates With Osteoporosis-Inducing Medications

  title={Risk of Fracture and the Concomitant Use of Bisphosphonates With Osteoporosis-Inducing Medications},
  author={Abner N Nyandege and Patricia W Slattum and Spencer E. Harpe},
  journal={Annals of Pharmacotherapy},
  pages={437 - 447}
Objective: To review the literature on the concomitant use of bisphosphonates and medications that can influence bone metabolism and potentially attenuate bisphosphonate antifracture efficacy. Data Sources: MEDLINE and CINAHL were searched for articles published in English through December 2014 using the following terms: bisphosphonates, bone density conservation agents, acid-suppressive therapy, levothyroxine, thiazolidinediones (TZDs), selective serotonin reuptake inhibitors (SSRIs), bone… Expand
Pharmaka mit negativer Auswirkung auf den Knochen - durch Medikamente induzierte Osteoporose
Lifestyle measures, an adequate supply of calcium and vitamin D and optionally a specific osteoporosis treatment with bisphosphonates, denosumab or teriparatide are appropriate are appropriate. Expand
  • Y. Liel, Y. Plakht, M. A. Tailakh
  • Medicine
  • Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
  • 2017
In this real-world study, the majority of women on prolonged oral bisphosphonates maintained bone resorption rates within the normal reference range for premenopausal women, and the likelihood for inadequate suppression was considerably greater than that of over-suppression. Expand
Therapiemöglichkeiten und Einschränkungen im höheren Alter bei Osteoporose
The article discusses individual decisions in elderly multimorbid patients and the persistence of antiosteoporotic medication seems to be very poor in elderly patients and appears to be better for parenteral formulations than for oral intake. Expand
Guidelines for the diagnosis, prevention and management of osteoporosis.
The Italian Society for Osteoporosis, Mineral Metabolism and Bone Diseases (SIOMMMS) has recently revised the previously published Guidelines on the diagnosis, riskassessment, prevention and management of primary and secondary osteoporotic disease. Expand
Non-destructive NIR spectral imaging assessment of bone water: Comparison to MRI measurements.
Since NIRSI requires minimal to no sample preparation, this approach has great potential to become a gold standard modality for the investigation of changes in water content, distribution, and environment in pre-clinical studies of bone pathology and therapeutics. Expand
Bergapten promotes bone marrow stromal cell differentiation into osteoblasts in vitro and in vivo
It is indicated that BP promotes the expression of alkaline phosphatase (ALP) by BMSCs in vitro in a dose-dependent manner, as revealed by ALP staining. Expand
Thyroid Hormones, Iodine and Iodides, and Antithyroid Drugs
Abstract In the current chapter, adverse reactions to thyroid hormones, thyroid hormone analogue eprotirome, octreotide, iodine, radioactive iodine, and antithyroid drugs thionamides which wereExpand
A Decade of Progress in Deep Brain Stimulation of the Subcallosal Cingulate for the Treatment of Depression
A comprehensive overview of the progress of DBS of the subcallosal cingulate in humans and the medial prefrontal cortex, its rodent homolog, for preclinical animal studies is provided and the various antidepressant-like behaviors induced by medial cortex DBS are discussed. Expand
Chapter 39 - Thyroid hormones, Iodine and Iodides, and Antithyroid Drugs
In the current chapter, adverse reactions to thyroid hormones, thyroid hormone analogue eprotirome, octreotide, iodine, radioactive iodine, and antithyroid drugs thionamides which were reported fromExpand
Protonenpumpeninhibitoren und Osteoporoserisiko
  • R. Gasser
  • Medicine
  • Journal für Mineralstoffwechsel & Muskuloskelettale Erkrankungen
  • 2020
Protonenpumpeninhibitoren (PPI) werden als Hemmer der Magensäuresekretion bei verschiedenen säureassoziierten Erkrankungen des oberen Gastrointestinaltrakts eingesetzt anderswo bei patients at risk for osteoporosis or with fracture risk. Expand


Fracture risk in patients receiving acid-suppressant medication alone and in combination with bisphosphonates
ASM is associated with an increased risk of fracture when taken alone or in combination with bisphosphonates, and the frequency of coprescription of ASM and bisph phosphonates requires further investigation. Expand
A review of the effect of anticonvulsant medications on bone mineral density and fracture risk.
Observational studies suggest an association between use of anticonvulsant medications, reduced bone mineral density, and increased fracture risk, and Randomized clinical trials are needed to guide the management of bone disease among those who use anticonVulsants. Expand
Safety Considerations with Bisphosphonates for the Treatment of Osteoporosis
The safety and tolerability profile of the nitrogen-containing bisphosphonates is good, and long-term treatment does not appear to carry a risk of serious AEs, and the authors’ experience has shown that encouraging adherence to administration instructions can minimise certain complications, such as UGI intolerability. Expand
Predictors of Fracture While on Treatment With Oral Bisphosphonates: A Population‐Based Cohort Study
Predictors of such fractures in a population‐based cohort of incident users of oral BPs found older age, underweight, vitamin D deficiency, PPI use, previous fracture, and inflammatory arthritides increase risk. Expand
Meta-analysis: risk of fractures with acid-suppressing medication.
There is some evidence for a modest association between PPI use and risk of fractures, which was not seen with H2RA exposure, which is most consistent for spine fractures, while there is substantial heterogeneity in the magnitude of risk for other fractures. Expand
Proton pump inhibitor use and the antifracture efficacy of alendronate.
BACKGROUND Proton pump inhibitors (PPIs) are widely used in elderly patients and are frequently coadministered in users of oral bisphosphonates. Biologically, PPIs could affect the absorption ofExpand
Vertebral fracture efficacy during risedronate therapy in patients using proton pump inhibitors
A post hoc analysis of a subset of patients participating in three prospective, randomized, placebo-controlled clinical trials, with durations of up to 3 years, showed that, regardless of PPI concomitant use, risedronate significantly reduced the risk of new vertebral fractures compared with placebo. Expand
Low-Energy Femoral Fractures Associated with the Long-Term Use of Bisphosphonates
Prescribers should be aware of the possibility of these rare adverse reactions and the prolonged use of bisphosphonates should be reconsidered until long-term robust safety data are available. Expand
Atypical fractures of the femur and bisphosphonate therapy: A systematic review of case/case series studies.
The results of this analysis allow identification of patients on bisphosphonate treatment at risk of developing atypical fractures, define fractures better as predominantly insufficiency fractures, illustrate that long-term bisph phosphate treatment is not a prerequisite for their development, and recognize the use of glucocorticoids and proton pump inhibitors as important risk factors. Expand
Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group.
The data suggest that risedronate therapy is effective and well tolerated in the treatment of women with established postmenopausal osteoporosis. Expand